Data on vericiguat, investigational heart failure medicine, to be presented as late-breaking clinical trial at the 2015 AHA Scientific Sessions
![](/46/pdcnewsitem/03/78/44/Merck2.jpg)
Vericiguat study in patients with worsening chronic heart failure and reduced ejection fraction.
Bayer and Merck (MDS outside the Us and Canada) have announced that new data on vericiguat (BAY 1021189), an investigational oral sGC (soluble guanylate cyclase) stimulator being codeveloped by Bayer and Merck for chronic heart failure and reduced left ventricular ejection fraction (HFrEF), will be presented at the upcoming American Heart Association (AHA) Scientific Sessions to be held 7–11 November 2015 in Orlando, Florida. The data were accepted as a late-breaking clinical trial presentation and are the results of the Phase IIb SOCRATES-REDUCED study. The objective of the study was to investigate the change over 12 weeks in NT-pro BNP (a blood marker of heart failure) to determine the appropriate dose of vericiguat for consideration in a Phase III clinical trial in patients with chronic HFrEF in addition to standard therapy.
The following data will be presented at AHA Scientific Sessions 2015:
Vericiguat Data Analysis
“Of the millions who suffer from heart failure, approximately half are estimated to have heart failure with reduced ejection fraction,” said Dr Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck Research Laboratories. “As a company, we feel it’s important to research additional treatment options for this disease.”
“Heart failure with reduced ejection fraction is an area of unmet need,” said Dario Mirski, vice president of US medical affairs, Bayer Pharmaceuticals. “At Bayer we’re committed to researching and advancing new therapies to help people with this condition.”
Vericiguat is part of a worldwide development collaboration between Merck and Bayer in the field of sGC modulation, which seeks to target a distinct molecular mechanism that is associated with the underlying pathophysiology of heart failure. The soluble guanylate cyclase (sGC) enzyme, which is important for the function of both the blood vessels and the heart, is insufficiently stimulated in heart failure due to impaired NO (nitric oxide) availability and endothelial dysfunction.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance